<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117472">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01573754</url>
  </required_header>
  <id_info>
    <org_study_id>FDA-2604</org_study_id>
    <secondary_id>R01FD002604</secondary_id>
    <secondary_id>UTMB, 02-435</secondary_id>
    <nct_id>NCT01573754</nct_id>
  </id_info>
  <brief_title>Hydroxychloroquine and Phlebotomy for Treating Porphyria Cutanea Tarda</brief_title>
  <official_title>A Prospective Comparison of Low Dose Hydroxychloroquine and Phlebotomy in the Treatment of Porphyria Cutanea Tarda. IRB 02-435</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Medical Branch, Galveston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Medical Branch, Galveston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Porphyria cutanea tarda (PCT) is an iron-related disorder that responds to treatment by
      phlebotomy or low-dose hydroxychloroquine, but comparative data on these treatments are
      limited. The hypothesis is that hydroxychloroquine is noninferior to phlebotomy in terms of
      time to remission. Patients with well documented PCT are assigned to treatment by
      randomization if specific criteria are met. All patients are followed until remission -
      defined as achieving a normal plasma porphyrin concentration.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Normal plasma porphyrin concentration</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Porphyria Cutanea Tarda</condition>
  <arm_group>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Phlebotomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>100 mg by mouth twice weekly</description>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
    <other_name>Plaquenil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Phlebotomy</intervention_name>
    <description>450 mL every 2 weeks</description>
    <arm_group_label>Phlebotomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented porphyria cutanea tarda (PCT)

          -  Willing to give informed consent

          -  Age 18 or greater

        Exclusion Criteria:

          -  Blistering skin lesions due to another condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karl E Anderson, MD</last_name>
      <phone>409-772-4661</phone>
      <email>kanderso@utmb.edu</email>
    </contact>
    <contact_backup>
      <last_name>Csilla K Hallberg, MD</last_name>
      <phone>409-772.4661</phone>
      <email>challberg@utmb.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Karl E Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>February 5, 2016</lastchanged_date>
  <firstreceived_date>April 5, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Porphyria, rare disease, orphan disease, iron metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Porphyrias</mesh_term>
    <mesh_term>Porphyria, Erythropoietic</mesh_term>
    <mesh_term>Porphyria Cutanea Tarda</mesh_term>
    <mesh_term>Porphyrias, Hepatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
